A systematic review of treatments of relapsed/refractory mantle cell lymphoma

Research output: Contribution to journalArticlepeer-review

Standard

A systematic review of treatments of relapsed/refractory mantle cell lymphoma. / Parrott, Madeliene; Rule, Simon; Kelleher, Michael; Wilson, Jayne.

In: Clinical Lymphoma Myeloma and Leukemia, Vol. 18, No. 1, 01.01.2018, p. 13-25.e6.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Parrott, Madeliene ; Rule, Simon ; Kelleher, Michael ; Wilson, Jayne. / A systematic review of treatments of relapsed/refractory mantle cell lymphoma. In: Clinical Lymphoma Myeloma and Leukemia. 2018 ; Vol. 18, No. 1. pp. 13-25.e6.

Bibtex

@article{947096f4eba34f7db5d2a058b4535ee3,
title = "A systematic review of treatments of relapsed/refractory mantle cell lymphoma",
abstract = "A systematic review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. The criteria for inclusion of the trials were established before the review. A search of Medline, Embase, and the Cochrane library databases was conducted to identify phase II or III randomized controlled trials (RCTs), reported from January 1, 1994 to May 29, 2016. Relevant conference abstracts, citation lists from the included articles, published guidelines, and on-going clinical trial databases were also searched. Studies were included if they had evaluated any single agent or combination of treatments for adult patients with relapsed/refractory MCL who had received ≥ 1 previous line of therapy. Seven RCTs were identified. Only 1 treatment appeared in > 1 trial; therefore, the results from each trial could not be quantitatively pooled for meta-analysis. The lack of common comparators, differences in baseline characteristics and inclusion and exclusion criteria, and variances in the response criteria used to measure outcomes made comparison of the results difficult. Although the direction of effect for progression-free survival (PFS) and overall survival (OS) was in favor of the experimental drug in all trials, the difference in PFS was statistically significant in 5 and OS in 2. None showed statistical significance for both. A noticeable lack of RCTs evaluating treatments for patients with relapsed/refractory MCL made meaningful comparisons of effectiveness across trials rather difficult. This trend continues, because all, bar 1, of the 85 ongoing trials in this area are single-arm studies. RCTs are required to enable better evaluation of the optimal treatment regimen for this group of patients.",
keywords = "B-cell lymphoma, MCL, non-Hodgkin lymphoma, randomized controlled trials, systematic published data review",
author = "Madeliene Parrott and Simon Rule and Michael Kelleher and Jayne Wilson",
year = "2018",
month = jan,
day = "1",
doi = "10.1016/j.clml.2017.10.004",
language = "English",
volume = "18",
pages = "13--25.e6",
journal = "Clinical Lymphoma Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Elsevier",
number = "1",

}

RIS

TY - JOUR

T1 - A systematic review of treatments of relapsed/refractory mantle cell lymphoma

AU - Parrott, Madeliene

AU - Rule, Simon

AU - Kelleher, Michael

AU - Wilson, Jayne

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A systematic review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. The criteria for inclusion of the trials were established before the review. A search of Medline, Embase, and the Cochrane library databases was conducted to identify phase II or III randomized controlled trials (RCTs), reported from January 1, 1994 to May 29, 2016. Relevant conference abstracts, citation lists from the included articles, published guidelines, and on-going clinical trial databases were also searched. Studies were included if they had evaluated any single agent or combination of treatments for adult patients with relapsed/refractory MCL who had received ≥ 1 previous line of therapy. Seven RCTs were identified. Only 1 treatment appeared in > 1 trial; therefore, the results from each trial could not be quantitatively pooled for meta-analysis. The lack of common comparators, differences in baseline characteristics and inclusion and exclusion criteria, and variances in the response criteria used to measure outcomes made comparison of the results difficult. Although the direction of effect for progression-free survival (PFS) and overall survival (OS) was in favor of the experimental drug in all trials, the difference in PFS was statistically significant in 5 and OS in 2. None showed statistical significance for both. A noticeable lack of RCTs evaluating treatments for patients with relapsed/refractory MCL made meaningful comparisons of effectiveness across trials rather difficult. This trend continues, because all, bar 1, of the 85 ongoing trials in this area are single-arm studies. RCTs are required to enable better evaluation of the optimal treatment regimen for this group of patients.

AB - A systematic review was conducted to evaluate the clinical effectiveness and safety of treatments for patients with relapsed/refractory mantle cell lymphoma (MCL) unsuitable for intensive treatment. The criteria for inclusion of the trials were established before the review. A search of Medline, Embase, and the Cochrane library databases was conducted to identify phase II or III randomized controlled trials (RCTs), reported from January 1, 1994 to May 29, 2016. Relevant conference abstracts, citation lists from the included articles, published guidelines, and on-going clinical trial databases were also searched. Studies were included if they had evaluated any single agent or combination of treatments for adult patients with relapsed/refractory MCL who had received ≥ 1 previous line of therapy. Seven RCTs were identified. Only 1 treatment appeared in > 1 trial; therefore, the results from each trial could not be quantitatively pooled for meta-analysis. The lack of common comparators, differences in baseline characteristics and inclusion and exclusion criteria, and variances in the response criteria used to measure outcomes made comparison of the results difficult. Although the direction of effect for progression-free survival (PFS) and overall survival (OS) was in favor of the experimental drug in all trials, the difference in PFS was statistically significant in 5 and OS in 2. None showed statistical significance for both. A noticeable lack of RCTs evaluating treatments for patients with relapsed/refractory MCL made meaningful comparisons of effectiveness across trials rather difficult. This trend continues, because all, bar 1, of the 85 ongoing trials in this area are single-arm studies. RCTs are required to enable better evaluation of the optimal treatment regimen for this group of patients.

KW - B-cell lymphoma

KW - MCL

KW - non-Hodgkin lymphoma

KW - randomized controlled trials

KW - systematic published data review

U2 - 10.1016/j.clml.2017.10.004

DO - 10.1016/j.clml.2017.10.004

M3 - Article

VL - 18

SP - 13-25.e6

JO - Clinical Lymphoma Myeloma and Leukemia

JF - Clinical Lymphoma Myeloma and Leukemia

SN - 2152-2650

IS - 1

ER -